Expertise in
1
conditions

Dr. Mamta Parikh

Internal Medicine
Glen Head, NY 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
1
conditions
Glen Head, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mamta Parikh is a primary care provider, practicing in Internal Medicine in Glen Head, New York. Dr. Parikh is highly rated in 1 condition, according to our data. Her top areas of expertise are Renal Cell Carcinoma (RCC), Penile Cancer, Ataxia-Telangiectasia, and Agranulocytosis.

Her clinical research consists of co-authoring 34 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Glen Head, NY 11545

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma and Other Genitourinary Tumors With DNA-Repair Defects
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, &Amp; Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Avelumab, Peposertib, Radium-223
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Cisplatin, Elimusertib, Gemcitabine Hydrochloride, BAY 1895344
Study Phase: Phase 1
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Radiation
Study Drug: Cabozantinib S-malate
Study Phase: Phase 2
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Cisplatin-Based Treatment is Not an Option
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug
Study Drugs: Atezolizumab, Eribulin Mesylate
Study Phase: Phase 2
A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial Carcinoma
A Phase Ib/II Study of Selinexor Plus Pembrolizumab in Cisplatin-Ineligible or Cisplatin-Refractory Patients With Advanced Urothelial Carcinoma
Enrollment Status: Terminated
Publish Date: January 29, 2026
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Selinexor
Study Phase: Phase 1/Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: October 27, 2025
Intervention Type: Drug
Study Drug: Adavosertib
Study Phase: Phase 2
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Docetaxel
Study Phase: Phase 2
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drugs: Cediranib, Olaparib
Study Phase: Phase 2
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-3475) for Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2025
Intervention Type: Procedure, Other, Biological
Study Drugs: Pembrolizumab, Recombinant EphB4-HAS Fusion Protein
Study Phase: Phase 2
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2024
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Niclosamide, Prednisone
Study Phase: Phase 2
Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)
Phase II Study of Neoadjuvant Atezolizumab-based Immunotherapy for Patients With Urothelial Carcinoma (NEBULA)
Enrollment Status: Completed
Publish Date: May 31, 2024
Intervention Type: Drug
Study Drug: MPDL3280A
Study Phase: Phase 2
A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Enrollment Status: Completed
Publish Date: April 26, 2023
Intervention Type: Drug
Study Drugs: Enzalutamide, Niclosamide
Study Phase: Phase 1
View 15 Less Clinical Trials

2 Total Publications

Development of a survey to assess the impact of substance use disorder education on student pharmacists' perspective.
Development of a survey to assess the impact of substance use disorder education on student pharmacists' perspective.
Journal: Currents in pharmacy teaching & learning
Published: June 25, 2021
Similar Doctors
Expertise in
33
conditions
Dr. Mark Lebwohl
Internal Medicine
Expertise in
33
conditions
Dr. Mark Lebwohl
Internal Medicine

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (19.3 miles away)
212-241-9728
Languages Spoken:
English
See accepted insurances

Mark Lebwohl is an Internal Medicine provider in New York, New York. Dr. Lebwohl is highly rated in 33 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP).

Expertise in
21
conditions
Dr. John Bilezikian
Internal Medicine
Expertise in
21
conditions
Dr. John Bilezikian
Internal Medicine

NewYork Presbyterian Columbia University Irving Medical Center

180 Fort Washington Ave, 
New York, NY 
 (18.4 miles away)
212-305-2663
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Bilezikian is an Internal Medicine provider in New York, New York. Dr. Bilezikian is highly rated in 21 conditions, according to our data. His top areas of expertise are Hyperparathyroidism, Hypoparathyroidism, Hypercalcemia, Parathyroidectomy, and Hormone Replacement Therapy (HRT).

Wilbert S. Aronow
Expertise in
52
conditions
Dr. Wilbert S. Aronow
Internal Medicine
Expertise in
52
conditions
Dr. Wilbert S. Aronow
Internal Medicine
23 Pebbleway Rd, 
New Rochelle, NY 
 (12.5 miles away)
914-493-5311
Languages Spoken:
English
See accepted insurances

Wilbert Aronow is a primary care provider, practicing in Internal Medicine in New Rochelle, New York. Dr. Aronow is highly rated in 52 conditions, according to our data. His top areas of expertise are Heart Failure, Heart Attack, Hypertension, Percutaneous Coronary Intervention (PCI), and Aortic Valve Replacement.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parikh's expertise for a condition
ConditionClose
      View All 114 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile